Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $86.9 million.

  • X4 Pharmaceuticals' Cash from Financing Activities changed N/A to $86.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 35749.9%. This contributed to the annual value of $20.3 million for FY2024, which is 7707.31% down from last year.
  • As of Q3 2025, X4 Pharmaceuticals' Cash from Financing Activities stood at $86.9 million.
  • In the past 5 years, X4 Pharmaceuticals' Cash from Financing Activities ranged from a high of $86.9 million in Q3 2025 and a low of -$4.4 million during Q3 2021
  • Over the past 5 years, X4 Pharmaceuticals' median Cash from Financing Activities value was $12.9 million (recorded in 2024), while the average stood at $24.6 million.
  • As far as peak fluctuations go, X4 Pharmaceuticals' Cash from Financing Activities plummeted by 152153.85% in 2021, and later skyrocketed by 2008213.26% in 2023.
  • Over the past 5 years, X4 Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $24.6 million in 2021, then soared by 146.82% to $60.6 million in 2022, then crashed by 99.84% to $97000.0 in 2023, then soared by 39.18% to $135000.0 in 2024, then surged by 64274.07% to $86.9 million in 2025.
  • Its Cash from Financing Activities was $86.9 million in Q3 2025, compared to $5.6 million in Q2 2025 and $135000.0 in Q4 2024.